Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual knockdown of Galectin-8 and its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth.
|
30905597 |
2019 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we studied DNA methylation status of the <i>ALCAM</i> gene using pyrosequencing in breast cancer tissues.
|
29315254 |
2018 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gold nanoprobe-based method for sensing activated leukocyte cell adhesion molecule (ALCAM) gene expression, as a breast cancer biomarker.
|
26923994 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we studied the association between ALCAM expression and tamoxifen resistance in ER + breast cancer and further investigated how ALCAM is regulated in the cancer cells.
|
28063929 |
2017 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, ALCAM-silenced breast cancer cells exhibited reduced binding to Gal-8 relative to control cells.
|
27130882 |
2016 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, these data demonstrate that ALCAM is generally expressed in normal and cancerous breast epithelium and that a marked reduction of ALCAM expression characterizes a subset of breast cancer patients with adverse tumor characteristics and unfavorable clinical outcome.
|
25270339 |
2014 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We tested the hypothesis that ALCAM expression would be markedly lower in cases of AA breast cancer when compared to CAU.
|
25255861 |
2014 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Little is known about the role of ALCAM levels in the serum of breast cancer patients.
|
22555284 |
2012 |
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in ALCAM and other chromosomal instability genes in breast cancer survival.
|
21935604 |
2012 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we evaluated the biologic effects of ALCAM expression in two breast cancer cell lines and a larger cohort of mammary carcinomas.
|
20972617 |
2011 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD166/ALCAM has gained increasing attention because of its significant association with tumor progression and the metastatic spread of breast cancer.
|
21293922 |
2011 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
To analyse the discriminative impact of osteopontin (OPN) and activated leukocyte cell adhesion molecule (ALCAM), combined with human epidermal growth factor 2 (HER2) and oestrogen receptor (ER) in breast cancer.
|
20736952 |
2010 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings offer insight into the mechanisms for down-regulation of ALCAM gene expression in tumor cells, and for the positive prognostic value of high-level ALCAM in breast cancer.
|
20929568 |
2010 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study investigated the biological influence of ALCAM on breast cancer cells in connection with bone biological environment.
|
20530423 |
2010 |
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The ALCAM transcript levels were lowest in patients with skeletal metastasis (p=0.0048) but were also significantly lower in patients who developed local recurrence (p=0.040) and in those who died from breast cancer (p=0.0075).
|
18202807 |
2008 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of ALCAM expression in relation to other molecular biomarkers revealed that ALCAM expression and the ALCAM/MMP-2 ratio are more promising indicators of breast cancer progression than MMP-2, E-cadherin, and alpha-catenin.
|
16810131 |
2006 |
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This report is the first evaluation of ALCAM/CD166 in an estrogen-dependent (MCF-7) and a metastatic (MDA-MB-231) breast cancer cell line and a reference breast cell line (HBL-100).
|
16865058 |
2006 |